Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study

BACKGROUND: Combination conversion therapies afforded curative surgery chance for initially unresectable hepatocellular carcinoma (uHCC). This study aimed to evaluate the conversion rate and clinical outcomes of a first-line conversion regimen of lenvatinib combined with transarterial chemoembolizat...

Descripción completa

Detalles Bibliográficos
Autores principales: Qu, Wei-Feng, Ding, Zhen-Bin, Qu, Xu-Dong, Tang, Zheng, Zhu, Gui-Qi, Fu, Xiu-Tao, Zhang, Zi-Han, Zhang, Xin, Huang, Ao, Tang, Min, Tian, Meng-Xin, Jiang, Xi-Fei, Huang, Run, Tao, Chen-Yang, Fang, Yuan, Gao, Jun, Wu, Xiao-Ling, Zhou, Jian, Fan, Jia, Liu, Wei-Ren, Shi, Ying-Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499852/
https://www.ncbi.nlm.nih.gov/pubmed/36125345
http://dx.doi.org/10.1093/bjsopen/zrac114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499852/
https://www.ncbi.nlm.nih.gov/pubmed/36125345
http://dx.doi.org/10.1093/bjsopen/zrac114

Ejemplares similares